Alladapt Immunotherapeutics is developing ADP101, an oral immunotherapy designed to mitigate food allergies by gradually increasing exposure to allergenic proteins under clinical supervision. This approach addresses the immune system's misrecognition of food proteins as harmful, impacting millions of individuals with food allergies and enhancing their quality of life.
Funding
$230.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of individuals suffer from food allergies, where the immune system mistakenly identifies food proteins as harmful. Current management strategies often involve strict avoidance of allergenic foods, which can be challenging and significantly impact quality of life, especially since many patients are allergic to multiple foods.
Solution
Alladapt Immunotherapeutics is developing ADP101, an investigational oral immunotherapy designed to address food allergies by gradually increasing exposure to allergenic proteins under clinical supervision. ADP101 aims to modulate the immune system's response to a broad range of common food allergens. The therapy is formulated to deliver consistent, well-characterized, and precisely dosed protein from multiple allergenic protein families. By remodeling the immune system through controlled exposure, Alladapt envisions a future where individuals with food allergies can experience a reduction in allergic reactions and improved quality of life.
Target Audience
The primary target audience includes individuals with food allergies, their families, and healthcare providers specializing in allergy and immunology.
Features
- Proprietary oral immunotherapy drug candidate (ADP101) designed for single or multiple food allergies
- Delivers highly consistent, well-characterized, precisely-dosed protein from a wide range of commonly allergenic protein families
- Based on intellectual property licensed from Stanford University, including patents and clinical data
- Currently in Phase 1/2 clinical trials (Harmony Study) evaluating safety and efficacy
- FDA Fast Track Designation for the treatment of mono- and multi-food allergies